|Bid||10.10 x 1200|
|Ask||10.10 x 800|
|Day's Range||9.73 - 11.11|
|52 Week Range||8.35 - 48.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.00|
Monopar Therapeutics Inc. (MNPR) today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate camsirubicin in the treatment of soft tissue sarcoma (STS), and the European Medicines Agency’s Committee for Orphan Medicinal Products has issued its public summary of opinion for the designation, which can be found on the Company’s website: https://www.monopartx.com/pipeline/Camsirubicin/development-strategy. Orphan Drug Designation: is given to medicinal products that represent a significant benefit over existing treatments; are intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating; and where prevalence of the condition in the European Union (EU) is less than 5 in 10,000 persons.
Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’ exercise of its over-allotment option, at a public offering price of $8.00 per share before underwriting discounts and commissions. Total net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $9.3 million from the initial public offering. JonesTrading Institutional Services LLC acted as Lead Bookrunning Manager and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as Co-Manager for the offering.
Monopar Therapeutics Inc. today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 166,666 shares of common stock. The closing is expected to occur on December 23, 2019, subject to customary closing conditions, bringing the total number of shares sold by Monopar Therapeutics in the initial public offering to 1,277,778 and total gross proceeds to approximately $10.2 million. The total net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $9.3 million from the initial public offering.
Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on December 19, 2019 under the symbol “MNPR.” The offering is expected to close on December 23, 2019, subject to the satisfaction of customary closing conditions. JonesTrading Institutional Services LLC acted as Lead Bookrunning Manager and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as Co-Manager for the offering.